Biogen Idec's BG-12 Results Up The Ante In The Oral MS Market
This article was originally published in The Pink Sheet Daily
Executive Summary
Biogen's drug is poised to become top dog among many oral MS drugs, including Novartis' approved Gilenya, analysts say.